These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25335824)

  • 21. Treatment of Parkinson's disease. Advances in the pharmacological therapy.
    Ghika J
    Eur Neurol; 1996; 36(6):396-9. PubMed ID: 8954312
    [No Abstract]   [Full Text] [Related]  

  • 22. L-dopa and (-)-deprenil in the treatment of Parkinson's disease: a long-term study [proceedings].
    Ambrozi L; Birkmayer W; Riederer P; Youdim MB
    Br J Pharmacol; 1976 Nov; 58(3):423P-424P. PubMed ID: 791430
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment of levodopa-induced motor complications.
    Stocchi F; Tagliati M; Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of motor symptoms in advanced Parkinson's disease: a practical approach.
    Maranis S; Tsouli S; Konitsiotis S
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Dec; 35(8):1795-807. PubMed ID: 21645577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.
    Pahwa R
    J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MAO type B inhibitors as adjunct to L-dopa therapy.
    Youdim MB; Finberg JP
    Adv Neurol; 1987; 45():127-36. PubMed ID: 3103383
    [No Abstract]   [Full Text] [Related]  

  • 27. Parkinson's disease: drug therapy.
    Oertel WH; Quinn NP
    Baillieres Clin Neurol; 1997 Apr; 6(1):89-108. PubMed ID: 9426870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New and emerging strategies for improving levodopa treatment.
    Tolosa ES; Valldeoriola F; Martí MJ
    Neurology; 1994 Jul; 44(7 Suppl 6):S35-44. PubMed ID: 8047259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Optimization of the treatment of Parkinson's disease using dopamine agonists].
    Rinne UK
    Arch Neurobiol (Madr); 1991; 54(6):282-7. PubMed ID: 1687430
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Drug therapy of Parkinson's disease].
    Myllylä V
    Duodecim; 1997; 113(18):1827-34. PubMed ID: 10892076
    [No Abstract]   [Full Text] [Related]  

  • 32. [Parkinson's disease].
    Mizuno Y
    No To Shinkei; 1994 Mar; 46(3):217-27. PubMed ID: 7910751
    [No Abstract]   [Full Text] [Related]  

  • 33. [Parkinson disease: interrogations and solutions].
    Allain H; Bentué-Ferrer D
    Presse Med; 1997 Jun; 26(19):909-15. PubMed ID: 9232065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of dopamine agonists and catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Inzelberg R; Carasso RL; Schechtman E; Nisipeanu P
    Clin Neuropharmacol; 2000; 23(5):262-6. PubMed ID: 11154093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parkinson's disease: the case for novel treatment strategies.
    Stern MB; Freese A
    Exp Neurol; 1997 Mar; 144(1):2-3. PubMed ID: 9126142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Levodopa: past, present, and future.
    Hauser RA
    Eur Neurol; 2009; 62(1):1-8. PubMed ID: 19407449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drugs for Parkinson's disease.
    Treat Guidel Med Lett; 2011 Jan; 9(101):1-6; quiz 2 p following 6. PubMed ID: 21304446
    [No Abstract]   [Full Text] [Related]  

  • 38. "Rational hope" in the early treatment of Parkinson's disease.
    Sourkes TL
    Can J Physiol Pharmacol; 1999 Jun; 77(6):375-82. PubMed ID: 10537223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
    Ries V; Selzer R; Eichhorn T; Oertel WH; Eggert K;
    Clin Neuropharmacol; 2010 May; 33(3):142-50. PubMed ID: 20502133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease.
    Devos D; Lejeune S; Cormier-Dequaire F; Tahiri K; Charbonnier-Beaupel F; Rouaix N; Duhamel A; Sablonnière B; Bonnet AM; Bonnet C; Zahr N; Costentin J; Vidailhet M; Corvol JC
    Parkinsonism Relat Disord; 2014 Feb; 20(2):170-5. PubMed ID: 24216088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.